ALZT-OP1a (cromolyn)

TargetCD33

Modalityrepurposed small molecule

IndicationAlzheimer's disease

PhasePhase 1 (Completed)

PartnerNone

Trial IDNCT04570644

Registry statusCOMPLETEDVerified 2026-10-05

Notes

Cromolyn sodium is an FDA-approved drug repurposed for its ability to modulate microglial activation state and promote phagocytosis by shifting CD33 / TREM2 balancing.

Source

Program entries are factual summaries of publicly disclosed clinical programs. Microglia.ai does not imply predictions about therapeutic outcomes or investment advice.

Last reviewed: October 5, 2026